Company

Durect

As of the edition of 20 October 2026, Durect runs 3 drugs, 1 of them marketed.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Drugs by status

StatusCount
Marketed1
Active1
Went quiet1
Total3

Marketed drugs and when their US protection ends

DrugUS protectionRoute B rows
Bupivacainenone listed1

A route B row is one company at one target.

Where its trials are

  • Digestive system: 3 trials led
  • Chemically induced: 2 trials led
  • Immune system: 1 trials led